• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自然杀伤细胞及其前体的分离、扩增与特性分析:作为研究癌症免疫监视的工具

Isolation, Expansion, and Characterization of Natural Killer Cells and Their Precursors as a Tool to Study Cancer Immunosurveillance.

作者信息

Parodi Monica, Meazza Raffaella, Vitale Chiara, Pietra Gabriella, Carrega Paolo, Vitale Massimo

机构信息

UOC Immunologia, IRCCS Ospedale Policlinico San Martino, Genova, Italy.

Department of Experimental Medicine (DIMES), University of Genova, Genoa, Italy.

出版信息

Methods Mol Biol. 2019;1884:87-117. doi: 10.1007/978-1-4939-8885-3_6.

DOI:10.1007/978-1-4939-8885-3_6
PMID:30465197
Abstract

This chapter will describe the current methodologies to isolate and expand NK cells from Peripheral Blood (PB) or tissues for "in vitro" studies, including NK cell antitumor immune function. In addition, methods to induce NK cell maturation, differentiation, and expansion from CD34 precursors will also be described. Finally, it will also be treated the topical issue of the characterization of new functionally and phenotypically defined NK cell subsets.

摘要

本章将描述从外周血(PB)或组织中分离和扩增自然杀伤(NK)细胞用于“体外”研究的当前方法,包括NK细胞的抗肿瘤免疫功能。此外,还将描述从CD34前体细胞诱导NK细胞成熟、分化和扩增的方法。最后,还将探讨新的功能和表型定义的NK细胞亚群特征这一热点问题。

相似文献

1
Isolation, Expansion, and Characterization of Natural Killer Cells and Their Precursors as a Tool to Study Cancer Immunosurveillance.自然杀伤细胞及其前体的分离、扩增与特性分析:作为研究癌症免疫监视的工具
Methods Mol Biol. 2019;1884:87-117. doi: 10.1007/978-1-4939-8885-3_6.
2
Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15.鉴定出一种新型人类脐带血CD34-CD133-CD7-CD45+谱系阴性细胞亚群,该亚群在体外暴露于白细胞介素-15后能够分化为淋巴细胞/NK细胞。
J Immunol. 2003 Sep 15;171(6):2977-88. doi: 10.4049/jimmunol.171.6.2977.
3
A Flow Cytometric NK Cell-Mediated Cytotoxicity Assay to Evaluate Anticancer Immune Responses In Vitro.一种用于体外评估抗癌免疫反应的流式细胞术自然杀伤细胞介导的细胞毒性测定法。
Methods Mol Biol. 2019;1884:131-139. doi: 10.1007/978-1-4939-8885-3_8.
4
CD107a Degranulation Assay to Evaluate Immune Cell Antitumor Activity.用于评估免疫细胞抗肿瘤活性的CD107a脱颗粒测定法。
Methods Mol Biol. 2019;1884:119-130. doi: 10.1007/978-1-4939-8885-3_7.
5
Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.具有低裂解活性的脐血CD16+56-细胞可能是成熟自然杀伤细胞的前体。
Cell Immunol. 1997 Sep 15;180(2):132-42. doi: 10.1006/cimm.1997.1175.
6
A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells.人类CD34(+)亚群存在于淋巴结中,并分化为CD56bright自然杀伤细胞。
Immunity. 2005 Mar;22(3):295-304. doi: 10.1016/j.immuni.2005.01.013.
7
TGF-β affects development and differentiation of human natural killer cell subsets.TGF-β 影响人自然杀伤细胞亚群的发育和分化。
Eur J Immunol. 2010 Aug;40(8):2289-95. doi: 10.1002/eji.200939910.
8
Tissue-resident cytotoxic innate lymphoid cells in tumor immunosurveillance.肿瘤免疫监视中的组织驻留细胞毒性固有淋巴细胞。
Semin Immunol. 2019 Feb;41:101269. doi: 10.1016/j.smim.2019.03.001. Epub 2019 Mar 21.
9
Differentiation of murine NK cells into distinct subsets based on variable expression of the IL-12R beta 2 subunit.基于IL-12Rβ2亚基的可变表达将小鼠自然杀伤细胞分化为不同亚群。
J Immunol. 2000 Nov 1;165(9):4985-93. doi: 10.4049/jimmunol.165.9.4985.
10
Subset analysis of human and mouse mature NK cells.人和小鼠成熟自然杀伤细胞的亚群分析。
Methods Mol Biol. 2010;612:27-38. doi: 10.1007/978-1-60761-362-6_3.

引用本文的文献

1
An Experimental Study Comparing the Expansion of Peripheral Blood Natural Killer (NK) Cells Cultured with Artificial Antigen-Presenting Cells, in the Presence or Absence of Bone Marrow Mesenchymal Stem Cells (MSCs).外周血自然杀伤(NK)细胞在人工抗原呈递细胞存在或不存在的情况下培养时的扩增比较的实验研究。
Mol Biotechnol. 2020 May;62(5):306-315. doi: 10.1007/s12033-020-00250-2.